PF-114 CML chronic myeloid leukemia
PF-114 is a third-generation oral tyrosine kinase inhibitor (TKI), which blocks native and mutated Bcr-Abl forms, including the T315I mutant.
CLINICAL TRIALS
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
August 31, 2016, ClinicalTrials.gov
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
August 31, 2016, ClinicalTrials.gov
ARTICLES
PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1T315I
Novembre 5, 2021, blood
PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I
November 2019, ASH 2019
PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells
May 14, 2019, PubMed
Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy
December 3, 2018, ASH 2018
PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy
December 2017, ASH 2017
Clinical features and outcomes in chronic myeloid leukemia with T315I mutation
July 31, 2017, Cellular Therapy and Transplantation
FDA assigns orphan status to a Russian drug
July 21, 2017, GMP news
PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells
October 8, 2015, Onco Clinical Hematology
New active substance effectively combats Philadelphia chromosome-positive leukaemia
November 29, 2014, News Medical
New substance overcomes treatment-resistance in leukemia
November 28, 2014, Science Daily
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome- positive (Ph+) leukemias harboring the T315I mutation
November 14, 2014, PubMed
PF-114, a Novel Selective Pan BCR/ABL Inhibitor Targets The T315I and Suppress Models Of Advanced Ph+ ALL
2013, Blood Journal
PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1T315I
Novembre 5, 2021, blood
PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I
November 2019, ASH 2019
PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells
May 14, 2019, PubMed
Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy
December 3, 2018, ASH 2018
PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy
December 2017, ASH 2017
Clinical features and outcomes in chronic myeloid leukemia with T315I mutation
July 31, 2017, Cellular Therapy and Transplantation
FDA assigns orphan status to a Russian drug
July 21, 2017, GMP news
PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells
October 8, 2015, Onco Clinical Hematology
New active substance effectively combats Philadelphia chromosome-positive leukaemia
November 29, 2014, News Medical
New substance overcomes treatment-resistance in leukemia
November 28, 2014, Science Daily
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome- positive (Ph+) leukemias harboring the T315I mutation
November 14, 2014, PubMed
PF-114, a Novel Selective Pan BCR/ABL Inhibitor Targets The T315I and Suppress Models Of Advanced Ph+ ALL
2013, Blood Journal
See also the T315I mutation